Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activity

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Zins, Karin ^a   Gunawardhana, Sandun ^a   Lucas, Trevor ^a   Abraham, Dietmar ^a   Aharinejad, Seyedhossein ^a  

^a Medical University of Vienna   (Austria)

Author keywords

Cancer therapy; Cdc42; Colon cancer; Rho GTPases; Small molecule inhibitor; Xenograft model

Indexed keywords

ANTINEOPLASTIC AGENT; AZA 197; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; N2 (4 DIETHYLAMINO 1 METHYL BUTYL) N4 [2 (1H INDOL 3 YL) ETHYL] 6 METHYL PYRIMIDINE 2,4 DIAMINE; P21 ACTIVATED KINASE 1; PROTEIN CDC42; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER SURGERY; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

3T3 CELLS; ACTIN CYTOSKELETON; ANIMALS; CDC42 GTP-BINDING PROTEIN; CELL DEATH; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONIC NEOPLASMS; DOWN-REGULATION; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; INDOLES; L-LACTATE DEHYDROGENASE; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; P21-ACTIVATED KINASES; PROTEIN BINDING; PYRIMIDINES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888269713     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-295     Document Type: Article

References (44)

1. Fritz G, Kaina B. Rho GTPases: promising cellular targets for novel anticancer drugs. Curr Cancer Drug Targets 2006, 6:1-14.
2. Walker K, Olson MF. Targeting Ras and Rho GTPases as opportunities for cancer therapeutics. Curr Opin Genet Dev 2005, 15:62-68. 10.1016/j.gde.2004.11.001, 15661535.
3. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009, 1796:91-98.
4. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008, 582:2093-2101. 10.1016/j.febslet.2008.04.039, 18460342.
5. Onesto C, Shutes A, Picard V, Schweighoffer F, Der CJ. Characterization of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. Methods Enzymol 2008, 439:111-129.
6. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 2004, 101:7618-7623. 10.1073/pnas.0307512101, 419655, 15128949.
7. Mardilovich K, Olson MF, Baugh M. Targeting Rho GTPase signaling for cancer therapy. Future Oncol 2012, 8:165-177. 10.2217/fon.11.143, 22335581.
8. Gomez del Pulgar T, Bandres E, Espina C, Valdes-Mora F, Perez-Palacios R, Garcia-Amigot F, Garcia-Foncillas J, Lacal JC. Differential expression of Rac1 identifies its target genes and its contribution to progression of colorectal cancer. Int J Biochem Cell Biol 2007, 39:2289-2302. 10.1016/j.biocel.2007.06.014, 17766170.
9. Espina C, Cespedes MV, Garcia-Cabezas MA, Gomez del Pulgar MT, Boluda A, Oroz LG, Benitah SA, Cejas P, Nistal M, Mangues R, Lacal JC. A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells. Am J Pathol 2008, 172:156-166. 10.2353/ajpath.2008.070561, 2189620, 18165265.
10. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999, 81:682-687. 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B, 10328216.
11. Cleverley SC, Costello PS, Henning SW, Cantrell DA. Loss of Rho function in the thymus is accompanied by the development of thymic lymphoma. Oncogene 2000, 19:13-20. 10.1038/sj.onc.1203259, 10644975.
12. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C, Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays 2005, 27:602-613. 10.1002/bies.20238, 15892119.
13. Braga VM, Yap AS. The challenges of abundance: epithelial junctions and small GTPase signalling. Curr Opin Cell Biol 2005, 17:466-474. 10.1016/j.ceb.2005.08.012, 16112561.
14. van Hengel J, D'Hooge P, Hooghe B, Wu X, Libbrecht L, De Vos R, Quondamatteo F, Klempt M, Brakebusch C, van Roy F. Continuous cell injury promotes hepatic tumorigenesis in cdc42-deficient mouse liver. Gastroenterology 2008, 134:781-792. 10.1053/j.gastro.2008.01.002, 18325391.
15. Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal 2011, 23:1415-1423. 10.1016/j.cellsig.2011.04.001, 3115433, 21515363.
16. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol 2006, 16:522-529. 10.1016/j.tcb.2006.08.006, 16949823.
17. Li LH, Zheng MH, Luo Q, Ye Q, Feng B, Lu AG, Wang ML, Chen XH, Su LP, Liu BY. P21-activated protein kinase 1 induces colorectal cancer metastasis involving ERK activation and phosphorylation of FAK at Ser-910. Int J Oncol 2010, 37:951-962.
18. Gomez Del Pulgar T, Valdes-Mora F, Bandres E, Perez-Palacios R, Espina C, Cejas P, Garcia-Cabezas MA, Nistal M, Casado E, Gonzalez-Baron M, et al. Cdc42 is highly expressed in colorectal adenocarcinoma and downregulates ID4 through an epigenetic mechanism. Int J Oncol 2008, 33:185-193.
19. Ferri N, Corsini A, Bottino P, Clerici F, Contini A. Virtual screening approach for the identification of new Rac1 inhibitors. J Med Chem 2009, 52:4087-4090. 10.1021/jm8015987, 19527032.
20. Zins K, Abraham D, Sioud M, Aharinejad S. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 2007, 67:1038-1045. 10.1158/0008-5472.CAN-06-2295, 17283136.
21. Aharinejad S, Abraham D, Paulus P, Abri H, Hofmann M, Grossschmidt K, Schafer R, Stanley ER, Hofbauer R. Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res 2002, 62:5317-5324.
22. Aharinejad S, Paulus P, Sioud M, Hofmann M, Zins K, Schafer R, Stanley ER, Abraham D. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res 2004, 64:5378-5384. 10.1158/0008-5472.CAN-04-0961, 15289345.
23. Shi HY, Stafford LJ, Liu Z, Liu M, Zhang M. Maspin controls mammary tumor cell migration through inhibiting Rac1 and Cdc42, but not the RhoA GTPase. Cell Motil Cytoskeleton 2007, 64:338-346. 10.1002/cm.20187, 17301947.
24. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995, 81:53-62. 10.1016/0092-8674(95)90370-4, 7536630.
25. Ye DZ, Field J. PAK signaling in cancer. Cell Logist 2012, 2:105-116. 10.4161/cl.21882, 3490961, 23162742.
26. Chong C, Tan L, Lim L, Manser E. The mechanism of PAK activation. Autophosphorylation events in both regulatory and kinase domains control activity. J Biol Chem 2001, 276:17347-17353. 10.1074/jbc.M009316200, 11278486.
27. Huynh N, Liu KH, Baldwin GS, He H. P21-activated kinase 1 stimulates colon cancer cell growth and migration/invasion via ERK- and AKT-dependent pathways. Biochim Biophys Acta 1803, 2010:1106-1113.
28. Nheu T, He H, Hirokawa Y, Walker F, Wood J, Maruta H. PAK is essential for RAS-induced upregulation of cyclin D1 during the G1 to S transition. Cell Cycle 2004, 3:71-74.
29. McCormick F. Success and failure on the ras pathway. Cancer Biol Ther 2007, 6:1654-1659. 10.4161/cbt.6.10.5153, 18245956.
30. Young A, Lyons J, Miller AL, Phan VT, Alarcon IR, McCormick F. Ras signaling and therapies. Adv Cancer Res 2009, 102:1-17.
31. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009, 27:663-671. 10.1200/JCO.2008.20.8397, 19114683.
32. de Toledo M, Anguille C, Roger L, Roux P, Gadea G. Cooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activity. PLoS One 2012, 7:e48344. 10.1371/journal.pone.0048344, 3492328, 23144867.
33. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, Ryan DP, Meyerhardt JA, Benes C, Settleman J, et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 2011, 121:4311-4321. 10.1172/JCI57909, 3204842, 21985784.
34. Surviladze Z, Waller A, Strouse JJ, Bologa C, Ursu O, Salas V, Parkinson JF, Phillips GK, Romero E, Wandinger-Ness A, et al. A Potent and Selective Inhibitor of Cdc42 GTPase 2010, Bethesda (MD): Probe Reports from the NIH Molecular Libraries Program.
35. Pelish HE, Peterson JR, Salvarezza SB, Rodriguez-Boulan E, Chen JL, Stamnes M, Macia E, Feng Y, Shair MD, Kirchhausen T. Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro. Nat Chem Biol 2006, 2:39-46. 10.1038/nchembio751, 16408091.
36. Friesland A, Zhao Y, Chen YH, Wang L, Zhou H, Lu Q. Small molecule targeting Cdc42-intersectin interaction disrupts Golgi organization and suppresses cell motility. Proc Natl Acad Sci USA 2013, 110:1261-1266. 10.1073/pnas.1116051110, 3557054, 23284167.
37. Li XR, Ji F, Ouyang J, Wu W, Qian LY, Yang KY. Overexpression of RhoA is associated with poor prognosis in hepatocellular carcinoma. Eur J Surg Oncol 2006, 32:1130-1134. 10.1016/j.ejso.2006.05.012, 16806792.
38. Huang M, Prendergast GC. RhoB in cancer suppression. Histol Histopathol 2006, 21:213-218.
39. Gao L, Bai L, Nan Q. Activation of Rho GTPase Cdc42 promotes adhesion and invasion in colorectal cancer cells. Med Sci Monit Basic Res 2013, 19:201-207. 3735386, 23884297.
40. Gadea G, Sanz-Moreno V, Self A, Godi A, Marshall CJ. DOCK10-mediated Cdc42 activation is necessary for amoeboid invasion of melanoma cells. Curr Biol 2008, 18:1456-1465. 10.1016/j.cub.2008.08.053, 18835169.
41. Kodama A, Takaishi K, Nakano K, Nishioka H, Takai Y. Involvement of Cdc42 small G protein in cell-cell adhesion, migration and morphology of MDCK cells. Oncogene 1999, 18:3996-4006. 10.1038/sj.onc.1202773, 10435623.
42. Zhao ZS, Manser E. PAK family kinases: physiological roles and regulation. Cell Logist 2012, 2:59-68. 10.4161/cl.21912, 3490964, 23162738.
43. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO, Konicek S, Hom J, Marshall M, Graff JR. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004, 10:3448-3456. 10.1158/1078-0432.CCR-03-0210, 15161701.
44. Qing H, Gong W, Che Y, Wang X, Peng L, Liang Y, Wang W, Deng Q, Zhang H, Jiang B. PAK1-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Tumour Biol 2012, 33:985-994. 10.1007/s13277-012-0327-1, 22252525.